Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.1.1.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.43.6 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBF.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.43.9 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XUNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.3 (Omicron)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.16.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.372NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.47NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.38NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.251NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.2.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.256NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.26NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.77NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.34NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.248NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.32NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.425NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.144NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.288NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.249NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.378NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.97NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.439NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.408NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.256NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Q.7 (Alpha)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.460NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.262NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBUNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.351.5 (Beta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FZ.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.9.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBC.1.6.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FQ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JB.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.3.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FZ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DV.7.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.30.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used